08:00 , Nov 8, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Metabolic syndrome; obesity Lacto-N-fucopentaose III (LNFPIII) In vitro and mouse studies suggest LNFPIII could help treat metabolic diseases. In macrophages, LNFPIII led to greater...